AD-SMART clinical trial tests diabetes and ADHD drugs for Alzheimer's

UK scientists launch AD-SMART clinical trial for Alzheimer's treatment

UK scientists have officially launched the AD-SMART clinical trial to investigate whether existing medications for diabetes and ADHD can be repurposed to treat Alzheimer's disease. This innovative study seeks to accelerate the delivery of effective treatments for the neurodegenerative condition by testing drugs that have already been approved for other uses. The trial focuses on whether these medications can effectively reduce memory loss and other cognitive symptoms associated with the disease. The trial will initially test two specific drugs: metformin, which is commonly used to manage type 2 diabetes, and atomoxetine, a medication primarily prescribed for Attention Deficit Hyperactivity Disorder (ADHD). By repurposing these existing treatments, researchers hope to bypass some of the lengthy early-stage safety testing required for entirely new compounds. This "smart" approach to clinical trials allows for multiple treatments to be tested simultaneously, significantly speeding up the research process. Supported by various health research organisations, the study aims to recruit approximately 1,200 participants across the United Kingdom. Participants like Angela Bucksey, who has already been diagnosed with Alzheimer’s, are joining the trial with a determination to combat the disease and contribute to a legacy of medical progress. The recruitment process is a critical component of the study, as researchers need a diverse and substantial cohort to ensure the statistical validity of the results. While the launch of the AD-SMART trial represents a significant step forward in dementia research, the findings will not be immediate. Researchers expect to yield initial results by 2030, marking a long-term commitment to understanding and treating the underlying causes of cognitive decline. If successful, this study could pave the way for more affordable and accessible treatments for millions of people living with Alzheimer's worldwide by utilizing drugs already present in the global pharmaceutical supply chain.